Associations of Digital Ulcers in Patients with Systemic Sclerosis: An 8-Year Retrospective Study.

IF 3 3区医学 Q2 DERMATOLOGY

Dermatology Pub Date : 2024-01-01 Epub Date: 2024-03-21 DOI:10.1159/000536030

Miaomiao Chi, Qi An, Xiuyuan Feng, Lan He, Ying Pan

{"title":"Associations of Digital Ulcers in Patients with Systemic Sclerosis: An 8-Year Retrospective Study.","authors":"Miaomiao Chi, Qi An, Xiuyuan Feng, Lan He, Ying Pan","doi":"10.1159/000536030","DOIUrl":null,"url":null,"abstract":"Introduction: This study aimed to investigate the associations of digital ulcers (DUs) in patients with systemic sclerosis (SSc).Methods: This retrospective study investigated the demographic characteristics, specific autoantibodies, organ involvement, and laboratory tests in patients with SSc from our hospital.Results: This study enrolled 144 patients with SSc. The DU+ group consisted of 15 (10.4%) patients. Patients with SSc having DUs have longer disease duration, higher fibrinogen, higher fibrin degradation product, and lower cholesterol. None of the patients used cholesterol-lowering drugs before onset of DUs. The study also demonstrated a higher prevalence of anti-dsDNA and anti-histone antibodies in patients with SSc with DUs. Anti-dsDNA antibody is a specific antibody for SLE with a specificity of 96-99%. A total of 86.1% (124/144) of patients suffered from diffuse cutaneous SSc, and 28.5% (41/144) of patients suffered from overlap syndrome.Conclusion: Our study indicated that patients with SSc with fibrinogen of >2.895 g/L (p = 0.043) and cholesterol of <3.340 mmol/L (p = 0.036), which is equal to 129.258 mg/dL, are at high risk of developing DUs.","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"387-396"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000536030","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This study aimed to investigate the associations of digital ulcers (DUs) in patients with systemic sclerosis (SSc).

Methods: This retrospective study investigated the demographic characteristics, specific autoantibodies, organ involvement, and laboratory tests in patients with SSc from our hospital.

Results: This study enrolled 144 patients with SSc. The DU+ group consisted of 15 (10.4%) patients. Patients with SSc having DUs have longer disease duration, higher fibrinogen, higher fibrin degradation product, and lower cholesterol. None of the patients used cholesterol-lowering drugs before onset of DUs. The study also demonstrated a higher prevalence of anti-dsDNA and anti-histone antibodies in patients with SSc with DUs. Anti-dsDNA antibody is a specific antibody for SLE with a specificity of 96-99%. A total of 86.1% (124/144) of patients suffered from diffuse cutaneous SSc, and 28.5% (41/144) of patients suffered from overlap syndrome.

Conclusion: Our study indicated that patients with SSc with fibrinogen of >2.895 g/L (p = 0.043) and cholesterol of <3.340 mmol/L (p = 0.036), which is equal to 129.258 mg/dL, are at high risk of developing DUs.

查看原文本刊更多论文

系统性硬化症患者数字溃疡的相关性：一项为期 8 年的回顾性研究。

导言本研究旨在探讨系统性硬化症（SSc）患者数字溃疡（DUs）的相关性：这项回顾性研究调查了我院SSc患者的人口统计学特征、特异性自身抗体、器官受累情况和实验室检查结果：本研究共纳入 144 名 SSc 患者。DU+组有15名患者（10.4%）。有DU的SSc患者病程较长，纤维蛋白原较高，纤维蛋白降解产物较高，胆固醇较低。这些患者在出现 DUs 前均未使用降胆固醇药物。该研究还表明，在有DUs的SSc患者中，抗dsDNA抗体和抗组蛋白抗体的发病率较高。抗dsDNA抗体是系统性红斑狼疮的特异性抗体，特异性高达96%-99%。共有86.1%（124/144）的患者患有弥漫性皮肤SSc，28.5%（41/144）的患者患有重叠综合征：我们的研究表明，纤维蛋白原>2.895 g/L (P = 0.043)和胆固醇>2.895 g/L (P = 0.043)的SSc患者，其血浆中的纤维蛋白原和胆固醇含量均高于正常人。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology 医学-皮肤病学

CiteScore

6.40

自引率

2.90%

发文量

审稿时长

1 months

期刊介绍： Published since 1893, ''Dermatology'' provides a worldwide survey of clinical and investigative dermatology. Original papers report clinical and laboratory findings. In order to inform readers of the implications of recent research, editorials and reviews prepared by invited, internationally recognized scientists are regularly featured. In addition to original papers, the journal publishes rapid communications, short communications, and letters to ''Dermatology''. ''Dermatology'' answers the complete information needs of practitioners concerned with progress in research related to skin, clinical dermatology and therapy. The journal enjoys a high scientific reputation with a continually increasing impact factor and an equally high circulation.